OnKure Therapeutics (OKUR) risk factors, FY2025 10-K

Risks Related to Our Operating History, Financial Position and Need for Additional Capital

1. 01We are early in our development efforts and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability
2. 02Our management has concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, substantial doubt exists as to our ability to continue as a going concernNew
3. 03We have incurred significant net losses in each period since inception, and we expect to continue to incur significant net losses for the foreseeable future
4. 04We have never generated revenue from product sales and may never achieve or maintain profitability
5. 05attracting, hiring and retaining qualified personnel86% rewritten

Risks Related to Our Development and Commercialization of Our Product Candidates

1. 06We are substantially dependent on OKI-219. If we are unable to advance OKI-219 through clinical development, obtain regulatory approval and ultimately commercialize such product candidate, or experience significant delays in doing so, our business will be materially harmed45% rewritten
2. 07the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
3. 08have regulatory authorities withdraw or suspend their approval of the product63% rewritten
4. 09Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
5. 10If we experience delays or difficulties in the enrollment or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
6. 11the risk that subjects enrolled in clinical trials will drop out of the trials before completion
7. 12The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities
8. 13suspensions or terminations by IRBs of the institutions at which such trials are being conducted, or by the FDA or other regulatory authorities due to a number of factors, including those described above
9. 14Interim, initial, “top-line,” and preliminary data from clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
10. 15Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
11. 16We may develop programs in combination with other therapies, which exposes us to additional risks
12. 17We face substantial competition which may result in others discovering, developing, or commercializing products before or more successfully than we do
13. 18Even if OKI-219 or any other product candidate receives marketing approval, they may fail to achieve market acceptance among physicians, patients, third-party payors, and others in the medical community
14. 19If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval
15. 20If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, if approved
16. 21Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations
17. 22A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
18. 23Increased tariffs on imports, including tariffs imposed by the United States and China, trade sanctions, other trade restrictions, or a global trade war could increase our costs and materially and adversely affect our business operations and financial conditionNew

Risks Related to Our Intellectual Property

1. 24countries other than the United States may have patent laws that are less favorable to patentees, allowing foreign competitors a better opportunity to create, develop and market competing products54% rewritten
2. 25Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time23% rewritten
3. 26preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the caseNew
4. 27Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
5. 28We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products26% rewritten
6. 29by the manufacture, use or sale of our product candidates or will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidatesNew
7. 30We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization of OKI-219 and any future product candidate
8. 31We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, or the patents or other intellectual property rights of any licensors, which could be expensive, time-consuming, and unsuccessful23% rewritten
9. 32terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employeesNew
10. 33Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
11. 34Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
12. 35We may not be able to protect our intellectual property rights throughout the world, which could impair our business
13. 36If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed73% rewritten
14. 37intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial conditionNew
15. 38We may become subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property
16. 39If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest, and our business may be adversely affected
17. 40Our intellectual property rights do not necessarily address all potential threats to our competitive advantage
18. 41we may fail to adequately protect and police our trademarks and trade secrets; and
19. 42Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
20. 43If we fail to comply with our obligations under any license, collaboration or other agreement, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates
21. 44In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities
22. 45We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties

Risks Related to Our Regulatory Approval and Other Legal Compliance Matters

1. 46injunctions or the imposition of civil or criminal penalties
2. 47We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
3. 48additional record-keeping requirements33% rewritten
4. 49the availability of capital
5. 50Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 51If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
7. 52We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations and can face serious consequences for violations
8. 53Restrictive laws and regulations govern the collection, use, transfer, and other processing of personal information

Risks Related to Our Reliance on Third Parties

1. 54We have relied upon, and plan to continue to rely upon, third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing clinical programs
2. 55the misappropriation of our proprietary information, including our trade secrets and know-how

Risks Related to Our Business Operations

1. 56Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 57If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
3. 58In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense65% rewritten

Risks Related to Ownership of Our Class A Common Stock

1. 59The market price of our Class A Common Stock has been and is expected to continue to be volatile
2. 60changes in accounting standards, policies, guidelines, interpretations or principles
3. 61We expect to incur losses for the foreseeable future and might never achieve profitability
4. 62If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan
5. 63We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies
6. 64We will continue to be an emerging growth company and a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our Class A Common Stock less attractive to investors
7. 65If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
8. 66Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and provisions of Delaware law could make acquiring us more difficult and may prevent attempts by our stockholders to replace or remove our management
9. 67require supermajority votes of the holders of our Common Stock to amend specified provisions of our Amended Certificate of Incorporation and Amended Bylaws
10. 68Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us
11. 69we may not retroactively amend the provisions of our Amended Bylaws to reduce our indemnification obligations to directors, officers, employees and agents
12. 70A robust trading market for our Class A Common Stock may not develop, and the holders of our Class A Common Stock may not be able to resell their shares of our Class A Common Stock for a profit, if at all
13. 71We could be subject to securities class action litigation, which is expensive and could divert management attention
14. 72Future sales of shares by existing stockholders could cause our Class A Common Stock price to decline53% rewritten
15. 73Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
16. 74If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, the stock price and trading volume of our Class A Common Stock could decline
17. 75We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition
18. 76Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger
19. 77Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows